Literature DB >> 8258702

Class II MHC transcriptional mutants are defective in higher order complex formation.

J L Riley1, J M Boss.   

Abstract

Human class II MHC genes are regulated in part by a series of conserved upstream sequence elements termed the X1, X2, and Y boxes. Class II MHC transcriptional mutant B cell lines have been defined that differ with regard to the presence of RFX, an X1 box DNA-binding activity. To further characterize these mutant cell lines, we tested the ability of these conserved upstream elements to respond to the presence of known transcriptional activation domains. A series of HLA-DRA promoter reporter constructions carrying Gal4 binding sites and GAL4 fusion protein expression vectors were cotransfected into both wild type B cells and mutant B cells representing the two RFX phenotypes. Regardless of RFX or class II phenotype, the activation domains of GAL4-VP16 and GAL4-E1a could synergistically stimulate expression of constructions containing both the X2 and Y boxes. GAL4-VP16- and GAL4-E1a-mediated expression was inhibited by the presence of the X1 box in cells that contained RFX. In mutant cells that lacked RFX, GAL4-VP16 activation was not inhibited. In the RFX-positive class II mutant cell line RJ2.2.5, the X1 box inhibitory activity could be overcome by separating the Gal4 site from the X1 box by two additional helical turns, suggesting that the RFX factor is bound at the X1 site and sterically interferes with activation. This was not the case in wild type B cells, suggesting that a stable higher order complex forms in wild type cells and not in the mutant cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258702

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  The transcriptional activation and repression domains of RFX1, a context-dependent regulator, can mutually neutralize their activities.

Authors:  Y Katan; R Agami; Y Shaul
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

4.  Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein.

Authors:  S K Mahanta; T Scholl; F C Yang; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5.

Authors:  J A Brown; X F He; S D Westerheide; J M Boss
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  Molecular characterization of chicken class II transactivator gene.

Authors:  Gholamreza Nikbakht Brujeni; Mohammad Khosravi
Journal:  Immunogenetics       Date:  2014-10-24       Impact factor: 2.846

7.  Mechanism of action of a distal NF-kappaB-dependent enhancer.

Authors:  Belete Teferedegne; Myesha R Green; Zhu Guo; Jeremy M Boss
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

8.  The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

Authors:  J A Brown; E M Rogers; J M Boss
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

9.  Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.

Authors:  Ann C Morris; Guy W Beresford; Myesha R Mooney; Jeremy M Boss
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.